What is the official website of Bristol Myers Squibb UK & Ireland ?

The official website of Bristol Myers Squibb UK & Ireland is http://www.bms.com/gb.

What is Bristol Myers Squibb UK & Ireland's cybersecurity risk score?

Bristol Myers Squibb UK & Ireland has an AI-generated cybersecurity risk score of 755 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Bristol Myers Squibb UK & Ireland experienced?

According to Rankiteo, Bristol Myers Squibb UK & Ireland currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Bristol Myers Squibb UK & Ireland been affected by any supply chain cyber incidents ?

According to Rankiteo, Bristol Myers Squibb UK & Ireland has been affected by multiple supply chain cyber incidents. The affected supply chain sources and their corresponding incident IDs are: Clario (Incident ID: ERT18610523) ERT (Incident ID: IQV125614222)

Does Bristol Myers Squibb UK & Ireland have SOC 2 Type 1 certification ?

According to Rankiteo, Bristol Myers Squibb UK & Ireland is not certified under SOC 2 Type 1.

Does Bristol Myers Squibb UK & Ireland have SOC 2 Type 2 certification ?

According to Rankiteo, Bristol Myers Squibb UK & Ireland does not hold a SOC 2 Type 2 certification.

Does Bristol Myers Squibb UK & Ireland comply with GDPR ?

According to Rankiteo, Bristol Myers Squibb UK & Ireland is not listed as GDPR compliant.

Does Bristol Myers Squibb UK & Ireland have PCI DSS certification ?

According to Rankiteo, Bristol Myers Squibb UK & Ireland does not currently maintain PCI DSS compliance.

Does Bristol Myers Squibb UK & Ireland comply with HIPAA ?

According to Rankiteo, Bristol Myers Squibb UK & Ireland is not compliant with HIPAA regulations.

Does Bristol Myers Squibb UK & Ireland have ISO 27001 certification ?

According to Rankiteo,Bristol Myers Squibb UK & Ireland is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Bristol Myers Squibb UK & Ireland operate in ?

Bristol Myers Squibb UK & Ireland operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Bristol Myers Squibb UK & Ireland have ?

Bristol Myers Squibb UK & Ireland employs approximately 319 people worldwide.

Does Bristol Myers Squibb UK & Ireland own any subsidiaries ?

Bristol Myers Squibb UK & Ireland presently has no subsidiaries across any sectors.

How many LinkedIn followers does Bristol Myers Squibb UK & Ireland have ?

Bristol Myers Squibb UK & Ireland's official LinkedIn profile has approximately 19,152 followers.

What is the NAICS classification code for Bristol Myers Squibb UK & Ireland ?

Bristol Myers Squibb UK & Ireland is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Bristol Myers Squibb UK & Ireland have a Crunchbase profile ?

No, Bristol Myers Squibb UK & Ireland does not have a profile on Crunchbase.

Does Bristol Myers Squibb UK & Ireland have a LinkedIn profile ?

Yes, Bristol Myers Squibb UK & Ireland maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/bristol-myers-squibb-uk-ireland.

How many cybersecurity incidents has Bristol Myers Squibb UK & Ireland experienced ?

As of July 18, 2026, Rankiteo reports that Bristol Myers Squibb UK & Ireland has experienced 3 cybersecurity incidents.

How many peer or competitor companies does Bristol Myers Squibb UK & Ireland have ?

Bristol Myers Squibb UK & Ireland has an estimated 5,710 peer or competitor companies worldwide.

What types of cybersecurity incidents has Bristol Myers Squibb UK & Ireland faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Ransomware and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

BMSUI

Boost Score +25 with badge (5 left)

755

/1000

Fair

780

/1000

Fair

Bristol Myers Squibb UK & Ireland Vendor Cyber Rating & Cyber Score

bms.com

Add Your Compliance Badge

Bristol Myers Squibb is a differentiated company, led by our revolutionary BioPharma strategy that combines the reach and resources of a major pharmaceutical firm with the entrepreneurial flair and swiftness of a biotech business. We strive to provide advanced medications for people struggling from life-threatening illnesses each and every day. Each day, our employees around the world work together for patients - it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, haematology, cardiology, immunology, fibrosis, and specialty medicines. Through our Research & Development organisation, we have built a sustainable pipeline of potential therapies, and actively partner

BMSUI A.I CyberSecurity Scoring

Scoring History

BMSUI

Bristol Myers Squibb UK & Ireland CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Bristol Myers Squib...

Cyber Attack

5/2023

BRI533080525

Bristol Myers Squib...

Ransomware

10/2020

Clario

ERT18610523

Bristol Myers Squib...

Ransomware

10/2020

ERT

IQV125614222

Loading…

A.I.

BMSUI Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for BMSUI

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Bristol Myers Squibb UK & Ireland in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Bristol Myers Squibb UK & Ireland in 2026.

Incident Types BMSUI vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Bristol Myers Squibb UK & Ireland in 2026.

Incident History - BMSUI (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Bristol Myers Squibb UK & Ireland Subsidiaries

BMSUI

Pharmaceutical Manufacturing

Website: http://www.bms.com/gb

Company Size: 319

Bristol Myers SquibbPharmaceutical Manufacturing

Loading…

Bristol Myers Squibb UK & Ireland Similar Companies

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Loading…

NEWS

Bristol Myers Squibb UK & Ireland CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 01, 2025 08:03 PM

Key facts: Bristol Myers Squibb showcases hematology data; plans $500M UK investment

Bristol Myers Squibb presented data at the ASH 2025 conference, focusing on the potential of its hematology pipeline and aiming to build...

Read Article

December 01, 2025 08:00 AM

Layoff Tracker: Valneva Terminates 30 Amid Site Closure

Below is a look at which companies have tightened their belts and cut staff during the second half of 2025. For first-half data,...

Read Article

November 13, 2025 08:00 AM

Global Inclusion

At Bristol Myers Squibb, we bring the best, most diverse minds to the table to serve the evolving needs of patients and communities.

Read Article

October 02, 2025 07:00 AM

Groups accuse drugmakers of conspiring to pressure UK over drug prices

UK advocacy groups ask CMA to probe alleged pharma coordination with US & UK trade groups to raise drug prices.

Read Article

October 01, 2025 07:00 AM

Big pharma is at war with the UK, and the government can’t back down now

The industry has always wanted the NHS to pay more for its drugs; now it is pulling research and investment out of Britain, says director of...

Read Article

September 30, 2025 07:00 AM

AbbVie joins BMS in taking a hard line on UK drug pricing

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.

Read Article

September 29, 2025 07:00 AM

AbbVie to launch ovarian cancer drug in UK at US price

AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the UK at a list price matching that in the U.S..

Read Article

September 24, 2025 07:00 AM

Bristol Myers to launch drug in the UK at the same price as in the US

The drug Cobenfy, used to treat schizophrenia, has an annual list price of USD 22500.

Read Article

September 23, 2025 07:00 AM

Schizophrenia drug from Bristol Myers gets price parity in UK

The news: Bristol Myers Squibb will launch its schizophrenia drug, Cobenfy, in the UK next year at the same price as in the US.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-57980

SUMMARY

Authentication bypass using an alternate path or channel in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform tampering over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-57980

CVE-2026-56741

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not apply an upper bound to terminal dimensions received via the Telnet NAWS option, and TelnetIO.handleNAWS() in TelnetIO.java:856-879 reads client-supplied width and height as 16-bit unsigned integers and passes values such as 65535x65535 to setTerminalGeometry(), allowing an unauthenticated remote attacker to repeatedly alternate values and trigger continuous expensive rendering work that causes CPU exhaustion and denial of service. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56740

SUMMARY

JLine is a Java library for handling console input. Prior to 3.30.14, 4.0.16, and 4.2.1, the JLine3 Telnet server remote-telnet module does not limit the number of environment variables a client may inject via the Telnet NEW-ENVIRON option, and TelnetIO.readNEVariables() in TelnetIO.java:1127-1180 stores each variable pair in a HashMap held by ConnectionData, allowing an unauthenticated attacker to flood unique variable pairs before the terminating IAC SE byte and exhaust JVM heap memory with an OutOfMemoryError. This issue is fixed in versions 3.30.14, 4.0.16, and 4.2.1.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56171

SUMMARY

Exposure of private personal information to an unauthorized actor in Windows RDP allows an unauthorized attacker to disclose information over a network.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:L/A:N

Impact Score

4.2

Exploitability

2.8

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-56171

CVE-2026-54335

SUMMARY

Feathersjs is a framework for creating web APIs and real-time applications with TypeScript or JavaScript. In 5.0.44 and earlier, the _.merge(target, source) utility exported by @feathersjs/commons recursively merges source into target by iterating Object.keys(source). When source was produced by JSON.parse and contains a __proto__, constructor, or prototype key, that key is returned as an own-enumerable property; the recursive merge then resolves target['__proto__'] to Object.prototype and writes attacker-supplied properties onto it, polluting the prototype for all plain objects in the process for the lifetime of the Node process. This issue is fixed in version 5.0.45.

Published

Date2026-07-17

Updated

Date2026-07-17

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N

Impact Score

1.4

Exploitability

2.2

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…